טוען...
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
BACKGROUND: Passive immunization against RSV (Respiratory Syncytial Virus) is given in most western countries (including Israel) to infants of high risk groups such as premature babies, and infants with Congenital Heart Disease or Congenital Lung Disease. However, immunoprophylaxis costs are extreme...
שמור ב:
| הוצא לאור ב: | Isr J Health Policy Res |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6296113/ https://ncbi.nlm.nih.gov/pubmed/30554570 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13584-018-0258-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|